Cargando…

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study

BACKGROUND: Bladder cancer is the 10th most common cancer globally, with a growing incidence in Japan. Evaluation of molecular, genetic, and cellular biomarkers that predict treatment response and prognosis in patients with metastatic urothelial carcinoma (mUC) may help optimize sequential treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishiyama, Hiroyuki, Tsuzuki, Toyonori, Ohyama, Chikara, Matsuyama, Hideyasu, Shinozaki, Kenta, Hayashi, Yuko, Hayashi, Nobuya, Koto, Ryo, Shin, Eisei, Ogawa, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543076/ https://www.ncbi.nlm.nih.gov/pubmed/37498492 http://dx.doi.org/10.1007/s10147-023-02386-y

Ejemplares similares

Mucin‐producing urothelial‐type adenocarcinoma of the prostate diagnosed after robot‐assisted radical prostatectomy
por: Shimizu, Kosuke, et al.
Publicado: (2021)

Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment
por: Miyake, Makito, et al.
Publicado: (2022)

Occurrence and Quantitative Microbial Risk Assessment of Methicillin-Resistant Staphylococcus aureus (MRSA) in a Sub-Catchment of the Yodo River Basin, Japan
por: Azuma, Takashi, et al.
Publicado: (2022)

Yodo tópico y glándula tiroidea. ¿Se debe tomar alguna precaución?
por: Castilla Guerra, Luis, et al.
Publicado: (2020)

Quantification of two aromatic amine mutagens, PBTA-1 and PBTA-2, in the yodo river system.
por: Ohe, T, et al.
Publicado: (1999)

Renal transplantation-related risk factors for the development of uterine adenomatoid tumors
por: Mizutani, Teruyuki, et al.
Publicado: (2016)

Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma
por: Iwamura, Hiromichi, et al.
Publicado: (2018)

The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
por: Uemura, Hiroji, et al.
Publicado: (2022)

Prevalencia de bocio y yodo-deficiencia en embarazadas indígenas de cinco áreas no metropolitanas de Colombia 2019
por: Herrera-Murgueitio, Julián Alberto, et al.
Publicado: (2021)

Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma
por: Mizuno, Tomoya, et al.
Publicado: (2021)

Editorial Comment to Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
por: Hatakeyama, Shingo, et al.
Publicado: (2020)

Indicadores para evaluar los trastornos por carencia de yodo y su control mediante la yodación de la sal.
Publicado: (1994)

Two cases of primary ovarian neuroblastoma arising from mature cystic teratomas()
por: Niwa, Yuri, et al.
Publicado: (2013)

Tumor heterogeneity evaluated by computed tomography detects muscle-invasive upper tract urothelial carcinoma that is associated with inflammatory tumor microenvironment
por: Goto, Keisuke, et al.
Publicado: (2021)

The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma
por: Inamoto, Teruo, et al.
Publicado: (2017)

Pulmones azules en pacientes COVID-19: un paso más allá del diagnóstico de tromboembolismo pulmonar mediante TCMD con mapa de yodo
por: Pérez Dueñas, Virginia, et al.
Publicado: (2021)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study
por: Hayashi, Kazuhiko, et al.
Publicado: (2018)

BALB/c-Fcgr2b(−/−)Pdcd1(−/−) mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis
por: Sugino, Yoshio, et al.
Publicado: (2012)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study
por: Yamada, Hideyasu, et al.
Publicado: (2022)

Correction to: Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study
por: Yamada, Hideyasu, et al.
Publicado: (2022)

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype
por: Satou, Akira, et al.
Publicado: (2019)

Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas
por: Satou, Akira, et al.
Publicado: (2022)

Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts
por: Samoto, Masahiro, et al.
Publicado: (2021)

The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis
por: Fujita, Kazutoshi, et al.
Publicado: (2022)

Thyroid Gland Flap for Minimally Invasive Reconstructive Head and Neck Surgery
por: Ogawa, Tetsuya, et al.
Publicado: (2020)

A Case of Low-Grade Oncocytic Tumor/Chromophobe Renal Cell Carcinoma (Oncocytic Variant) of the Kidney
por: Ishikawa, Noriyoshi, et al.
Publicado: (2021)

Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
por: Aizawa, Rihito, et al.
Publicado: (2022)

Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment
por: Chen, Ji, et al.
Publicado: (2022)

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer
por: Miura, Yuki, et al.
Publicado: (2021)

N‐glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas
por: Kodama, Hirotake, et al.
Publicado: (2021)

Hodgkin Lymphoma: Biology and Differential Diagnostic Problem
por: Takahara, Taishi, et al.
Publicado: (2022)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
por: Okuyama, Yoshiharu, et al.
Publicado: (2021)

Klinefelter syndrome: From pediatrics to geriatrics
por: Shiraishi, Koji, et al.
Publicado: (2018)

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
por: Ozaki, Kai, et al.
Publicado: (2021)

Immunological microenvironment in the testis
por: Qu, Ning, et al.
Publicado: (2019)

Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e7m1ta9cdenvg7u35c3aqfna5s